126 related articles for article (PubMed ID: 2516692)
61. Fibrin/fibrinogen degradation products (FDP) in urine and serum after prolonged heavy exercise.
Arnesen H; Akesson I; Strömme SB; Refsum HE
Scand J Haematol; 1976 Apr; 16(4):279-84. PubMed ID: 935811
[TBL] [Abstract][Full Text] [Related]
62. An immunohistochemical study of experimental disseminated intravascular coagulation (DIC).
Toyofuku H; Hayashi K; Awai M
Acta Pathol Jpn; 1987 Aug; 37(8):1279-90. PubMed ID: 3314332
[TBL] [Abstract][Full Text] [Related]
63. Fibrin/fibrinogen degradation products (FDP) at hospital admission predict neurological outcomes in out-of-hospital cardiac arrest patients.
Ono Y; Hayakawa M; Maekawa K; Kodate A; Sadamoto Y; Tominaga N; Murakami H; Yoshida T; Katabami K; Wada T; Sageshima H; Sawamura A; Gando S
Resuscitation; 2017 Feb; 111():62-67. PubMed ID: 27940211
[TBL] [Abstract][Full Text] [Related]
64. Measurement of cross linked fibrin derivatives in plasma: an immunoassay using monoclonal antibodies.
Whitaker AN; Elms MJ; Masci PP; Bundesen PG; Rylatt DB; Webber AJ; Bunce IH
J Clin Pathol; 1984 Aug; 37(8):882-7. PubMed ID: 6206097
[TBL] [Abstract][Full Text] [Related]
65. The significance of the fibrin/fibrinogen degradation product in serum of carcinoma patients with hematogenous metastasis.
Imaoka S; Sasaki Y; Iwanaga T; Terasawa T
Cancer; 1986 Oct; 58(7):1488-92. PubMed ID: 3742466
[TBL] [Abstract][Full Text] [Related]
66. [Clinical significance of urinary FDP-E measured by latex photometric immunoassay (LPIA) in the renal disease].
Kaizu K; Ito Y; Uriu K; Komine N; Hashimoto O; Eto S
Nihon Jinzo Gakkai Shi; 1991 Apr; 33(4):365-71. PubMed ID: 1875556
[TBL] [Abstract][Full Text] [Related]
67. Incidence and clinical significance of elevated fibrin(ogen) degradation product and/or D-dimer levels in liver cirrhosis patients.
Cioni G; Cristani A; Mussini C; Grandi S; Pentore R; Zeneroli ML; Tizzanini W; Zagni G; Ventura E
Ital J Gastroenterol; 1990 Apr; 22(2):70-4. PubMed ID: 2131934
[TBL] [Abstract][Full Text] [Related]
68. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
69. [Urinary cross-linked FDP in various renal diseases].
Inuma H
Nihon Jinzo Gakkai Shi; 1994 Feb; 36(2):146-57. PubMed ID: 8139147
[TBL] [Abstract][Full Text] [Related]
70. Determination of urinary fibrin/fibrinogen degradation products by radioimmunoassay.
Ekberg M; Hedner U; Larsson I; Nilsson IM; Nosslin B
Scand J Clin Lab Invest; 1976 Sep; 36(5):453-9. PubMed ID: 790536
[TBL] [Abstract][Full Text] [Related]
71. False-negative test for fibrinogen--fibrin degradation products.
Kickler T; Bell WR
Am J Clin Pathol; 1977 Jul; 68(1):78-80. PubMed ID: 868807
[TBL] [Abstract][Full Text] [Related]
72. [Analysis of FDP subfragments--application of the western blot].
Takahashi S; Kitagawa T
Nihon Jinzo Gakkai Shi; 1987 Feb; 29(2):151-5. PubMed ID: 3298756
[No Abstract] [Full Text] [Related]
73. Comparisons of hemagglutination inhibition, staphylococcal clumping, and latex agglutination tests for canine fibrinolytic degradation products.
Chen JP; Williams TK; Legendre AM
Am J Vet Res; 1981 Dec; 42(12):2049-52. PubMed ID: 7340573
[TBL] [Abstract][Full Text] [Related]
74. [Urinary FDP D-dimer and E fragments in renal transplantation].
Akiyama T; Ikegami M; Imanishi M; Ishii T; Nishioka T; Uemura T; Kunikata S; Mitsubayashi S; Kanda H; Matsuura T
Nihon Hinyokika Gakkai Zasshi; 1990 Nov; 81(11):1680-5. PubMed ID: 2287115
[TBL] [Abstract][Full Text] [Related]
75. Significance of urinary fibrin/fibrinogen degradation products in renal diseases measured by a highly sensitive ELISA.
Shibata T; Magari Y; Perparim K; Sumie A; Ishii T; Tomo T; Sato J; Yasumori R; Nasu M
Nephron; 1995; 69(1):54-8. PubMed ID: 7891798
[TBL] [Abstract][Full Text] [Related]
76. Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products.
Kogan AE; Mukharyamova KS; Bereznikova AV; Filatov VL; Koshkina EV; Bloshchitsyna MN; Katrukha AG
Blood Coagul Fibrinolysis; 2016 Jul; 27(5):542-50. PubMed ID: 26656897
[TBL] [Abstract][Full Text] [Related]
77. [Persistent discrepancy between FDP and D-dimer in a patient with acute leukemia].
Sato N; Takahashi H; Nikuni K; Seki Y; Wada K; Tatewaki W; Shibata A
Rinsho Ketsueki; 1995 Mar; 36(3):212-7. PubMed ID: 7783324
[TBL] [Abstract][Full Text] [Related]
78. A quantitative enzyme immunoassay for primary fibrinogenolysis products in plasma.
Koppert PW; Kuipers W; Hoegee-de Nobel B; Brommer EJ; Koopman J; Nieuwenhuizen W
Thromb Haemost; 1987 Feb; 57(1):25-8. PubMed ID: 2438796
[TBL] [Abstract][Full Text] [Related]
79. [Recent progress on analysis of blood coagulation factors and fibrinolytic agents; FDP D dimer analysis using NANOPIA FDP].
Matsumoto T; Sakai Y; Maeda M; Takei F
Rinsho Byori; 1989 Apr; Spec No 81():183-8. PubMed ID: 2754806
[No Abstract] [Full Text] [Related]
80. Comparative evaluation of whole blood D-dimer test to plasma D-dimer test for diagnosis of disseminated intravascular coagulation.
Gupta PK; Gupta M; Chatterjee T; Saxena R
Indian J Exp Biol; 2005 Apr; 43(4):382-4. PubMed ID: 15875726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
